miR-183-5p Inhibits Occurrence and Progression of Acute Myeloid Leukemia via Targeting Erbin

Molecular Therapy : the Journal of the American Society of Gene Therapy
Zhuojun ZhengJingting Jiang

Abstract

Erbin has been shown to have significant effects on the development of solid tumors. However, little is known about its function and regulatory mechanism in hematological malignancies. The biological function of Erbin on cell proliferation was measured in vitro and in vivo. The predicted target of Erbin was validated by dual-luciferase reporter assay and rescue experiment. We found that overexpression of Erbin could inhibit the cell proliferation and promote the cell differentiation of acute myeloid leukemia (AML) cells, whereas depletion of Erbin could enhance the cell proliferation and block the cell differentiation in AML cells in vitro and in vivo. Besides, miR-183-5p was identified as the upstream regulator that negatively regulated the Erbin expression. The results were confirmed by dual-luciferase reporter and RNA pull-down assay. Furthermore, we found that miR-183-5p negatively regulated Erbin, resulting in enhanced cell proliferation of AML cells via activation of RAS/RAF/MEK/ERK and PI3K/AKT/FoxO3a pathways. The activation of RAS/RAF/MEK/ERK and PI3K/AKT/FoxO3a pathways was mediated by Erbin interacting with Grb2. These results were also validated by rescue experiments in vitro and in vivo. All above-mentioned finding...Continue Reading

Citations

Jan 15, 2020·Annals of Hematology·Mingyu LiHongzai Guan
Oct 2, 2020·Oncogene·Marie-Josée SantoniJean-Paul Borg
Apr 10, 2020·Arteriosclerosis, Thrombosis, and Vascular Biology·Changbin SunBo Yu
Aug 18, 2020·OncoTargets and Therapy·Ruowen Guo, Yide Qin
May 28, 2019·Journal of Hematology & Oncology·Yan LiuLin Fu
Jan 26, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Soudeh Ghafouri-FardMohammad Taheri
Jun 10, 2021·Communications Biology·Silke PudewellMohammad R Ahmadian

❮ Previous
Next ❯

Methods Mentioned

BETA
two-hybrid
Flow cytometry
flow
confocal microscopy
PMA
transfection
Assay
pull-down
co-IP
Co-immunoprecipitation

Software Mentioned

FACSDiva
BD CellQuest Pro
Modfit
FlowJo
GraphPad
SPSS
GraphPad Prism
ImageJ

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukaemia & RNA

Acute myeloid leukaemia (AML) is a common hematological type of cancer. As the population ages, there has been a rise in the frequency of AML. RNA expression has been used to see if there are different genetic profiles that exist within AML and whether these may underpin the variations in survival rates. Here is the latest research on AML and RNA.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

© 2022 Meta ULC. All rights reserved